General
Preferred name
EZOGABINE
Synonyms
RETIGABINE HYDROCHLORIDE ()
D-23129 ()
Retigabine dihydrochloride ()
retigabine ()
N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid|D-23129 ()
Retigabine 2HCl ()
N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid (2HCl), D-23129 2HCl ()
D-23129, N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid ()
AWD-21360 ()
WAY-143841 ()
GW-582892X ()
GW582892X ()
GKE-841 ()
AWD21-360 ()
Potiga ()
Trobalt ()
Retigabine ()
Retigabine ()
Retigabine (hydrochloride) ()
P&D ID
PD009342
CAS
150812-13-8
150812-12-7
Tags
natural product
drug
available
Approved by
EMA
FDA
First approval
2011
Drug Status
investigational
approved
withdrawn
Drug indication
Epilepsy
Behcet disease
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Retigabine is unique among antiepileptic drugs in that it functions by activating selected voltage-gated potassium channels in the brain (i.e. Kv7 family channels) . (GtoPdb)
TOXICITY Lethal Dose, acute, oral, rat = 100 mg/kg;; Lethal Dose, chronic, oral, rat = 5.1 mg/kg/day, 90-day;; Most common adverse effects that lead to discontinuation of therapy include dizziness and somnolence.
ABSORPTION Rapidly absorbed and distributed, with an absolute oral bioavailability of 60%. Pharmacokinetics of ezogabine suggest first-order kinetics. ; Tmax, single oral dose = 30-120 minutes; ; Time to steady state = 3 days
DESCRIPTION Retigabine is unique among antiepileptic drugs in that it functions by activating selected voltage-gated potassium channels in the brain (i.e. Kv7 family channels) .
Cell lines
1
Organisms
1
Compound Sets
21
AdooQ Bioactive Compound Library
A15222
Axon Medchem Screening Library
1525
2252
Cayman Chemical Bioactives
21449
39309
ChEMBL Approved Drugs
CHEMBL41355
ChEMBL Drugs
CHEMBL41355
Concise Guide to Pharmacology 2017/18
2601
Concise Guide to Pharmacology 2019/20
2601
Concise Guide to Pharmacology 2021/22
2601
Concise Guide to Pharmacology 2023/24
2601
DrugBank
DB04953
DrugBank Approved Drugs
DB04953
DrugCentral
4181
DrugCentral Approved Drugs
4181
DrugMAP
DMGNYIH
DrugMAP Approved Drugs
DMGNYIH
DrugMatrix
Guide to Pharmacology
2601
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL41355
ReFrame library
Selleckchem Bioactive Compound Library
retigabine
retigabine-2hcl
TargetMol Bioactive Compound Library
T21487
External IDs
53
Properties
(calculated by RDKit )
Molecular Weight
303.14
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
2
cLogP
3.59
TPSA
76.38
Fraction CSP3
0.19
Chiral centers
0.0
Largest ring
6.0
QED
0.74
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Membrane Transporter/Ion Channel
Target
KCNQ3/5
KCNQ2/Q3
KCQN4
KCNQ channel opener
Potassium Channel
Therapeutic Class
Anticonvulsants
Source data